Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxymorphone - Endo Pharmaceuticals

Drug Profile

Oxymorphone - Endo Pharmaceuticals

Alternative Names: EN 3202; EN 3203; Opana; Opana ER

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endo Pharmaceuticals
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Musculoskeletal pain
  • Phase III Postoperative pain

Most Recent Events

  • 30 Jul 2019 Oxymorphone is still in phase III development for Post-operative pain (In infants, In neonates) in USA (NCT02687451)
  • 30 Jul 2019 No development reported - Phase-III for Postoperative pain (In children) in USA (PO) (NCT00801398)
  • 25 Jul 2019 Endo Pharmaceuticals suspends a phase III trial in Postoperative pain (In neonates, In infants) in USA (Parenteral) (PO) as the company was awaiting for the US FDA feedback (NCT02687451)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top